EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer

Mohammed Muqeet Adnan, Usman Bhutta, Tanzeel Iqbal, Sufyan AbdulMujeeb, Lukas Haragsim, Syed Amer

Case Reports in Nephrology · 2014 · 2014 · 1-3

DOI: 10.1155/2014/565393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Nephrology, 2014. Verfasst von Mohammed Muqeet Adnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Denosumab is a monoclonal antibody used for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcemia after the administration of the drug. The patient’s vitamin D levels were low when checked after administration of the drug, which likely predisposed him to the development of hypocalcemia. He was placed on high doses of oral and intravenous (IV) calcium and vitamin D without any appreciable response in the serum calcium level. His ionized calcium remained below 0.71 mmol/L despite very high doses of oral and IV calcium supplements. During the hospital course, he developed hydronephrosis from the spread of a tumor and did not want to undergo percutaneous nephrostomy tube placement; therefore, it was decided to dialyse him for acute renal failure and to correct his hypocalcemia. Checking calcium and vitamin D levels prior to the administration of Denosumab is vital in preventing hypocalcemia. If hypocalcemia is severe and not responsive to high doses of vitamin D, oral and IV calcium, then hemodialysis with a high calcium bath can correct this electrolyte abnormality.

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
  • Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA ; Department of Nephrology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
  • University of Illinois at Chicago, Chicago, IL 60607, USA.
  • Department of Nephrology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
  • Department of Internal Medicine, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.

Zitieren

APA

Muqeet Adnan, M., Bhutta, U., Iqbal, T., AbdulMujeeb, S., Haragsim, L., & Amer, S. (2014). Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer. Case Reports in Nephrology, 2014, 1-3. https://doi.org/10.1155/2014/565393

Vancouver

Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S. Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer. Case Reports in Nephrology. 2014;2014:1-3. doi:10.1155/2014/565393

BibTeX
@article{MuqeetAdnan2014,
  author = {Muqeet Adnan, Mohammed and Bhutta, Usman and Iqbal, Tanzeel and AbdulMujeeb, Sufyan and Haragsim, Lukas and Amer, Syed},
  title = {Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer},
  journal = {Case Reports in Nephrology},
  year = {2014},
  volume = {2014},
  pages = {1--3},
  doi = {10.1155/2014/565393}
}
Kostenlos starten →